Steven S. Williamson - 03 Mar 2025 Form 4 Insider Report for Pulmonx Corp (LUNG)

Role
PRESIDENT AND CEO, Director
Signature
/s/ David Aaron Lehman, Attorney-in-Fact
Issuer symbol
LUNG
Transactions as of
03 Mar 2025
Transactions value $
-$197,699
Form type
4
Filing time
05 Mar 2025, 18:09:24 UTC
Previous filing
22 Aug 2024
Next filing
04 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LUNG Common Stock Sale -$197,699 -27,689 -12% $7.14 194,342 03 Mar 2025 Direct F1, F2
transaction LUNG Common Stock Award $0 +181,696 +93% $0 376,038 03 Mar 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LUNG Employee Stock Option (right to buy) Award $0 +128,395 $0 128,395 03 Mar 2025 Common Stock 128,395 $8.29 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 15, 2024.
F2 Includes 2,500 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on February 21, 2025.
F3 Represents grant of RSUs payable solely in common stock of the Issuer that vest in equal quarterly installments over the four-year period from the grant date of March 3, 2025.
F4 The shares subject to the option vest in 48 equal monthly installments from the grant date on March 3, 2025.